{"denoms":[{"counts":[{"groupId":"BG000","value":"284"},{"groupId":"BG001","value":"285"},{"groupId":"BG002","value":"569"}],"units":"Participants"}],"groups":[{"description":"Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"BG000","title":"Everolimus + Vinorelbine + Trastuzumab"},{"description":"Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)","id":"BG001","title":"Placebo + Vinorelbine + Trastuzumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.98","value":"54.3"},{"groupId":"BG001","spread":"11.00","value":"53.4"},{"groupId":"BG002","spread":"10.99","value":"53.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"284"},{"groupId":"BG001","value":"285"},{"groupId":"BG002","value":"569"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients."}